Is it feasible for a 58-year-old woman taking trazodone 150 mg daily, an unidentified medication (Islamic) 150 mg daily, lurasidone (Latuda) 20 mg daily, and olanzapine 5 mg daily to discontinue lurasidone and rely on olanzapine instead, and what is the best approach?

Discontinuing Latuda and Relying on Olanzapine: Feasibility and Approach

Yes, it is feasible to discontinue lurasidone (Latuda) 20 mg and increase olanzapine instead, but this requires careful consideration of the underlying diagnosis, current symptom control, and metabolic risk profile. The patient is already on a complex polypharmacy regimen that needs clarification and optimization.

Critical First Step: Clarify the Diagnosis and Medication Regimen

Before making any changes, you must determine:

• What is the primary diagnosis? (Schizophrenia, bipolar depression, or major depressive disorder with psychotic features)
• What is "Islamic 150 mg"? This appears to be a transcription error and needs immediate clarification, as it may represent lamotrigine, escitalopram, or another medication that could significantly impact treatment decisions
• Why is the patient on both lurasidone AND olanzapine simultaneously? This represents antipsychotic polypharmacy, which should generally be avoided unless there's a specific indication 1

Assessment of Current Situation

The patient is experiencing treatment failure with lurasidone 20 mg, which is actually the starting dose. According to FDA labeling, the therapeutic dose range for lurasidone is 40-120 mg/day for schizophrenia and 20-120 mg/day for bipolar depression, with 80 mg/day being the maximum recommended dose for most patients 2. The patient may simply be underdosed rather than experiencing true treatment failure.

Decision Algorithm

If the diagnosis is Schizophrenia:

1. First, optimize lurasidone dosing before abandoning it entirely. Increase to 40-80 mg/day and reassess after 4 weeks of therapeutic dosing 3
2. If inadequate response persists after 4 weeks at therapeutic dose (40-80 mg/day), then switch to olanzapine monotherapy
3. Switching strategy: Use gradual cross-titration over 1-2 weeks. As you increase olanzapine (target 10-20 mg/day), taper lurasidone by 20 mg every 3-5 days 3
4. Critical caveat: Olanzapine carries significant metabolic risks. At age 58, this patient needs baseline and ongoing monitoring of weight, glucose, lipids, and HbA1c. Consider concurrent metformin prophylaxis 3

If the diagnosis is Bipolar I Depression:

1. Lurasidone is FDA-approved and evidence-based for bipolar depression with favorable metabolic profile 2, 4
2. Current dose (20 mg) is subtherapeutic for most patients. Increase to 40-80 mg/day before declaring failure 5
3. Olanzapine is NOT FDA-approved as monotherapy for bipolar depression (only as olanzapine-fluoxetine combination)
4. If switching is still desired: Olanzapine monotherapy has less evidence for bipolar depression than lurasidone, and carries substantially higher metabolic risk 4

Specific Switching Protocol (If Proceeding)

Week 1:

• Increase olanzapine from 5 mg to 10 mg daily
• Continue lurasidone 20 mg

Week 2:

• Increase olanzapine to 15 mg daily
• Reduce lurasidone to 10 mg (or discontinue if 10 mg not available)

Week 3:

• Target olanzapine dose 15-20 mg daily
• Discontinue lurasidone

Critical Safety Considerations

Metabolic Monitoring (Essential with Olanzapine)

Olanzapine has one of the highest risks for weight gain and metabolic syndrome among antipsychotics. In studies, 34.4% of patients gained ≥7% body weight on olanzapine versus 5.9% on lurasidone 6. At age 58, this patient is at higher risk for:

• Type 2 diabetes
• Dyslipidemia
• Cardiovascular disease

Mandatory monitoring:

• Baseline: Weight, BMI, waist circumference, fasting glucose, HbA1c, lipid panel
• Follow-up: Weight at every visit, metabolic labs at 3 months, then every 6 months

Drug Interaction Warning

There is a documented case report of probable serotonin syndrome when trazodone 100 mg was combined with lurasidone and valproic acid 7. If the unidentified "Islamic 150 mg" medication is valproic acid or another serotonergic agent, the combination with trazodone 150 mg requires careful monitoring for serotonin syndrome symptoms (agitation, confusion, tremor, muscle rigidity, hyperthermia).

Antipsychotic Polypharmacy Concerns

The current regimen includes both lurasidone and olanzapine simultaneously, which constitutes antipsychotic polypharmacy. According to guidelines, monotherapy should be the goal 1. The combination increases:

• Total antipsychotic burden and side effect risk
• Drug-drug interaction potential
• Cost and complexity
• Risk of non-adherence

This regimen needs rationalization regardless of which antipsychotic is chosen.

Alternative Recommendation

Rather than switching, consider optimizing the current regimen:

1. Discontinue one antipsychotic (likely lurasidone since patient reports it's "not working")
2. Optimize olanzapine dosing to 10-20 mg/day as monotherapy
3. Clarify and optimize the other medications in the regimen
4. Implement metabolic risk mitigation: Consider prophylactic metformin, dietary counseling, exercise program
5. Reassess in 4-6 weeks with standardized symptom rating scales

Bottom Line

The switch is feasible but may not be optimal. The patient's lurasidone dose is subtherapeutic, and increasing it to 40-80 mg/day may provide adequate response without the metabolic burden of higher-dose olanzapine. If switching proceeds, use gradual cross-titration over 2-3 weeks, implement aggressive metabolic monitoring and prophylaxis, and ensure the underlying diagnosis and complete medication list are clarified before making definitive changes.